Vaxcyte (NASDAQ:PCVX) EVP Sells $84,461.96 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,381 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $61.16, for a total value of $84,461.96. Following the completion of the sale, the executive vice president owned 152,228 shares in the company, valued at $9,310,264.48. This trade represents a 0.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Trading Up 1.0%

Shares of NASDAQ PCVX opened at $59.47 on Friday. The stock’s 50-day moving average is $58.44 and its 200 day moving average is $56.34. The stock has a market cap of $8.85 billion, a price-to-earnings ratio of -7.79 and a beta of 1.22. Vaxcyte, Inc. has a 1-year low of $30.81 and a 1-year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09. During the same period in the previous year, the business posted ($1.22) earnings per share. On average, analysts forecast that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in shares of Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after purchasing an additional 600 shares during the period. IFP Advisors Inc raised its holdings in Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after purchasing an additional 236 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after buying an additional 184 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after buying an additional 1,350 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

PCVX has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $98.00.

Vaxcyte Company Profile

Vaxcyte, Inc is a clinical-stage biotechnology company focused on developing vaccines to prevent serious bacterial infections. The company’s lead programs target pneumococcal disease, which can cause pneumonia, meningitis, bloodstream infections and other invasive illnesses. Vaxcyte is developing broad-spectrum pneumococcal conjugate vaccine candidates designed to protect against a wide range of bacterial serotypes.

Vaxcyte’s pipeline has included VAX-24, an investigational 24-valent pneumococcal conjugate vaccine, and VAX-31, a next-generation candidate designed to cover 31 serotypes.